Ira Gantz

Publication Activity (10 Years)

Years Active: 2017-2021
Publications (10 Years): 7

Top Topics

Skeletal Muscle

Top Venues

Diabetes, obesity & metabolism

Diabetes therapy : research, treatment and education of diabetes and related disorders

International journal of clinical practice

Cardiovascular diabetology

This page only lists publications with an associated author ORCID identifier.

Publications

Takashi Kadowaki, Yutaka Seino, Kohei Kaku, Taro Okamoto, Miho Kameya, Asako Sato, Tomona Hirano, Nobuyuki Oshima, Ira Gantz, Edward A O'Neill, Samuel S Engel, null null
A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control. Diabetes, obesity & metabolism 23 (6) (2021)
Ronan Roussel, Santiago Duran-García, Yilong Zhang, Suneri Shah, Carolyn Darmiento, R Ravi Shankar, Gregory T Golm, Raymond L H Lam, Edward A O'Neill, Ira Gantz, Keith D Kaufman, Samuel S Engel
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study. Diabetes, obesity & metabolism 21 (4) (2018)
Ira Gantz, Menghui Chen, Shailaja Suryawanshi, Catherine Ntabadde, Sukrut Shah, Edward A O'Neill, Samuel S Engel, Keith D Kaufman, Eseng Lai
A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovascular diabetology 16 (1) (2017)
Ira Gantz, Taro Okamoto, Yuka Ito, Kotoba Okuyama, Edward A O'Neill, Keith D Kaufman, Samuel S Engel, Eseng Lai, null null
A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes. Diabetes, obesity & metabolism 19 (11) (2017)
Seung-Hwan Lee, Ira Gantz, Elizabeth Round, Melanie Latham, Edward A O'Neill, Paulette Ceesay, Shailaja Suryawanshi, Keith D Kaufman, Samuel S Engel, Eseng Lai
A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin. BMC endocrine disorders 17 (1) (2017)
Ira Gantz, Taro Okamoto, Yuka Ito, Asako Sato, Kotoba Okuyama, Edward A O'Neill, Samuel S Engel, Eseng Lai, null null
A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control. Diabetes therapy : research, treatment and education of diabetes and related disorders 8 (4) (2017)
Antonio Chacra, Ira Gantz, Geraldine Mendizabal, Lucila Durlach, Edward A O'Neill, Zachary Zimmer, Shailaja Suryawanshi, Samuel S Engel, Eseng Lai
A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment. International journal of clinical practice 71 (6) (2017)